Ozempic for PCOS and insulin resistance: what the data says

What did @primalpcos actually say?

The creator argues that semaglutide (Ozempic) is "more problematic" for people with insulin resistance who don't have type 2 diabetes, specifically because one of its mechanisms stimulates the pancreas to release more insulin. For PCOS patients, they claim this extra insulin pushes the ovaries to produce more testosterone, worsening symptoms like hair growth, acne, and irregular ovulation. They position metformin as the safer alternative because it doesn't trigger additional insulin secretion.

They're not saying Ozempic is dangerous across the board. They're making a narrower, mechanism-based argument: the drug's glucose-dependent insulinotropic action is useful when your pancreas is underperforming (type 2 diabetes), but potentially counterproductive when your pancreas is already working overtime and your cells simply aren't responding.

Does the science back this up?

Partially, yes, but with meaningful caveats the video skips over. The core physiology is real. Semaglutide does stimulate glucose-dependent insulin secretion from pancreatic beta cells. And hyperinsulinemia is a well-documented driver of androgen excess in PCOS, operating through both ovarian theca cell stimulation and suppression of sex hormone-binding globulin (SHBG). Rosenfield and Ehrmann (2016, New England Journal of Medicine) laid this out clearly in their review of PCOS pathophysiology.

But here's where the argument gets complicated. Semaglutide's insulin-stimulating effect is glucose-dependent, meaning it diminishes significantly when blood sugar is low or normal. In practice, GLP-1 receptor agonists have shown reductions in fasting insulin and HOMA-IR in women with PCOS in several small trials, including Salameh et al. (2021, Frontiers in Endocrinology). The net metabolic effect isn't simply "more insulin." The drug also reduces glucagon, slows gastric emptying, and improves peripheral insulin sensitivity indirectly through weight loss. The creator's framing omits this nuance.

What did they get wrong (or right)?

They got the basic mechanism of hyperinsulinemia's role in PCOS right. That part is textbook endocrinology and worth saying out loud on a platform where most creators aren't engaging with mechanisms at all. Credit where it's due.

What they oversimplified: the claim that stimulating insulin release will automatically "make your symptoms worse" in insulin-resistant PCOS patients doesn't hold up cleanly against the clinical data. A 2023 randomized trial by Elkind-Hirsch et al. (Diabetes, Obesity and Metabolism) found that liraglutide, another GLP-1 agonist, significantly reduced androgen levels and improved menstrual regularity in women with PCOS and obesity, precisely the population the creator says would be harmed.

They also overstate metformin's clean advantage. Metformin does avoid direct insulin secretagogue activity, but its benefits in PCOS are modest and inconsistent across body weight categories, per a Cochrane review (Pfeifer et al., 2019). Saying metformin "does this without stimulating the release of insulin" is accurate in mechanism but misleading if it implies metformin is clearly superior for all insulin-resistant PCOS patients.

The thyroid cancer warning is appropriate. Semaglutide carries an FDA black box warning for medullary thyroid carcinoma risk based on rodent data, and patients with a personal or family history of MTC or MEN2 should avoid it.

What should you actually know?

The relationship between GLP-1 agonists and PCOS is genuinely unsettled science, and that's the honest answer. There is no FDA-approved treatment specifically for PCOS. Semaglutide is not part of the standard clinical framework for PCOS management, which is accurate. But "not standard" is different from "harmful," and the video blurs that line.

If you have PCOS with insulin resistance and your physician is considering semaglutide, the relevant questions are about your specific metabolic profile, your weight status, and what's driving your symptoms most. The glucose-dependent nature of GLP-1-stimulated insulin release means the theoretical worsening the creator describes is more nuanced in practice than the video suggests.

• Semaglutide only stimulates insulin when blood glucose is elevated, not continuously.
• Weight loss from GLP-1 agonists can independently lower insulin and androgen levels in PCOS.
• Metformin remains a first-line option in many guidelines, but its efficacy varies significantly.
• Neither drug is approved specifically for PCOS, and off-label decisions require individualized assessment.

The creator is right to tell viewers to talk to their doctor. That part shouldn't get lost in the mechanistic debate.